Roivant CEO Matt Gline at #BIO24 (Brian Benton Photography)
Roivant brings rare disease program closer as Immunovant CEO retires
Roivant is changing its strategy for Immunovant roughly a month after its subsidiary decided it wouldn’t take one of its drugs to the FDA despite …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
